"Lymphotoxin-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR.
| Descriptor ID |
D008233
|
| MeSH Number(s) |
D12.644.276.374.480.438 D12.644.276.374.750.500 D12.776.467.374.480.438 D12.776.467.374.750.500 D23.529.374.480.438 D23.529.374.750.500
|
| Concept/Terms |
Lymphotoxin-alpha- Lymphotoxin-alpha
- Lymphotoxin alpha
- Lymphotoxin
- Tumor Necrosis Factor-beta
- Tumor Necrosis Factor beta
- TNF-beta
- Tumor Necrosis Factor Ligand Superfamily Member 1
- alpha-Lymphotoxin
- alpha Lymphotoxin
- TNF Superfamily, Member 1
Lymphotoxin-alpha3- Lymphotoxin-alpha3
- Lymphotoxin alpha3
- Soluble Lymphotoxin-alpha
- Lymphotoxin-alpha, Soluble
- Soluble Lymphotoxin alpha
|
Below are MeSH descriptors whose meaning is more general than "Lymphotoxin-alpha".
Below are MeSH descriptors whose meaning is more specific than "Lymphotoxin-alpha".
This graph shows the total number of publications written about "Lymphotoxin-alpha" by people in this website by year, and whether "Lymphotoxin-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphotoxin-alpha" by people in Profiles.
-
Cohort study on the differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke. J Cereb Blood Flow Metab. 2022 10; 42(10):1827-1839.
-
Establishment of Elevated Serum Levels of IL-10, IL-8 and TNF-? as Potential Peripheral Blood Biomarkers in Tubercular Lymphadenitis: A Prospective Observational Cohort Study. PLoS One. 2016; 11(1):e0145576.
-
Lymphotoxin alpha-deficient mice clear persistent rotavirus infection after local generation of mucosal IgA. J Virol. 2013 Jan; 87(1):524-30.
-
Identification of novel susceptibility genes in ozone-induced inflammation in mice. Eur Respir J. 2010 Aug; 36(2):428-37.
-
Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen. J Immunol. 2006 Jul 01; 177(1):290-7.
-
Lymphotoxin-alpha and cardiovascular disease: clinical association and pathogenic mechanisms. Med Sci Monit. 2006 Jul; 12(7):RA121-4.
-
Gene expression profiling and analysis of signaling pathways involved in priming and differentiation of human neural stem cells. Neuroscience. 2006; 138(1):133-48.
-
Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis Rheum. 2005 Oct; 52(10):3202-9.
-
Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2004 Jul; 50(7):2140-50.
-
Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov; 17(11):2196-201.